Potent, exceptionally selective, orally bioavailable inhibitors of TNF-α Converting Enzyme (TACE): Novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1′ substituents

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 5, 2008, Pages 1577-1582

  Ott, Gregory R ^a   Asakawa, Naoyuki ^a   Lu, Zhonghui ^a   Anand, Rajan ^a   Liu, Rui Qin ^a   Covington, Maryanne B ^a   Vaddi, Krishna ^a   Qian, Mingxin ^a   Newton, Robert C ^a   Christ, David D ^a   Trzaskos, James M ^a   Duan, James J W ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

Matrix metalloprotease; MMP; TACE; TNF modulator; TNF Converting Enzyme

Indexed keywords

ADAM PROTEIN; BENZAMIDE DERIVATIVE; HYDROXAMIC ACID DERIVATIVE; INTERSTITIAL COLLAGENASE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BLOOD; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; NONHUMAN;

ADAM PROTEINS; ANIMALS; AREA UNDER CURVE; BENZAMIDES; BIOLOGICAL AVAILABILITY; DOGS; HALF-LIFE; MOLECULAR STRUCTURE; RATS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 39849103710     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.01.075     Document Type: Article

References (20)

1. Newton R.C., and Decicco C.P. J. Med. Chem. 42 (1999) 2295
2. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., and Blosch C.M. N. Engl. J. Med. 337 (1997) 141
3. Lipsky P.E., van der Heijde D.M.F.M.E., St. Clair W., Furst D.E., Breedveld F.C., Kalden J.R., Smolen J.S., Weisman M., Emery P., Feldmann M., Harriman G.R., and Maini R.N. N. Engl. J. Med. 343 (2000) 1594
4. Machold K.P., and Smolen J.S. Exp. Opin. Bio. Ther. 3 (2003) 351
5. Black R.A. Int. J. Biochem. Cell Biol. 34 (2002) 1
6. For a recent review see. Skotnicki J.S., and Levin J.I. Ann. Rep. Med. Chem. 38 (2003) 153
7. Duan J.J.-W., Chen L., Wasserman Z.R., Lu Z., Liu R.-Q., Covington M.B., Qian M., Hardman K.D., Magolda R.L., Newton R.C., Christ D.D., Wexlre R.R., and Decicco C.P. J. Med. Chem. 45 (2002) 4954
8. Xue C.-B., He X., Roderick J., Corbett R.L., Duan J.J.-W., Liu R.-Q., Covington M.B., Newton R.C., Trzaskos J.M., Magolda R.L., Wexler R.R., and Decicco C.P. Bioorg. Med. Chem. Lett. 13 (2003) 4293
9. Xue C.-B., He X., Roderick J., Corbett R.L., Duan J.J.-W., Liu R.-Q., Covington M.B., Qian M., Ribadeneira M.D., Vaddi K., Christ D.D., Newton R.C., Trzaskos J.M., Magolda R.L., Wexler R.R., and Decicco C.P. Bioorg. Med. Chem. Lett. 13 (2003) 4299
10. Gilmore J.L., King B.W., Harris C., Maduskuie T., Mercer S.E., Liu R., Covington M.B., Qian M., Ribadeneria M.D., Vaddi K., Trzaskos J.M., Newton R.C., Duan J.J.-W., and Decicco C.P. Bioorg. Med. Chem. Lett. 16 (2006) 2699
11. Duan J.J.-W., Chen L., Lu Z., Xue C.-B., Liu R.-Q., Covington M.B., Qian M., Wasserman Z.R., Vaddi K., Christ D.D., Trzaskos J.M., Newton R.C., and Decicco C.P. Bioorg. Med. Chem. Lett. 18 (2008) 241
12. Ott G.R., Asakawa N., Lu Z., Liu R.-Q., Covington M.B., Vaddi K., Qian M., Newton R.C., Christ D.D., Trzaskos J.M., and Decicco C.P. Bioorg. Med. Chem. Lett. 18 (2008) 694
13. Xue C.-B., Chen X.T., He X., Roderick J., Corbett R.L., Ghavimi B., Liu R.-Q., Covington M.B., Qian M., Ribadeneira M.D., Vaddi K., Trzaskos J., Newton R.C., Duan J.J.-W., and Decicco C.P. Bioorg. Med. Chem. Lett. 14 (2004) 4453
14. Levitt N.C., Eskens F.A.L.M., O'Byrne K.J., Propper D.J., Denis L.J., Owen S.J., Choi L., Foekens J.A., Wilner S., Wood J.M., Nakajima M., Talbot D.C., Steward W.P., Harris A.L., and Verweij J. Clin. Cancer Res. 7 (2001) 1912
15. Details of the pTACE (porcine TACE), MMPs, human whole blood (WBA) assays as well as LPS-mouse efficacy model are reported in previous publication, see. Xue C.-B., Voss M.E., Nelson D.J., Duan J.J.-W., Cherney R.J., Jacobson I.C., He X., Roderick J., Chen L., Corbett R.L., Wang L., Meyer D.T., Kennedy K., DeGrado W.F., Hardman K.D., Teleha C.A., Jaffee B.D., Liu R.-Q., Copeland R.A., Covington M.B., Christ D.D., Trzaskos J.M., Newton R.C., Magolda R.L., Wexler R.R., and Decicco C.P. J. Med. Chem. 44 (2001) 2636
16. 1H NMR and mass spectral data. 2-(1,1-difluoro-ethyl)-1H-benzo[d]imidazole and 2-(1-fluoro-1-methyl-ethyl)-1H-benzo[d]imidazole used to prepare compounds 28, 30, and 31 were synthesized from o-phenylenediamine and the corresponding carboxylic acids, 2,2-difluoropropanoic acid, and 2-fluoroisobutyric acid, via two-step procedure involving BOP reagent coupling to form the mono-amide and cyclization with AcOH. For a similar benzimidazole cyclization procedure see. Fonseca T., Gigante B., and Gilchrist T.L. Tetrahedron 57 (2001) 1793
17. Artursson P., Palm K., and Luthman K. Adv. Drug Delivery Rev. 22 (1996) 67
18. Wu J.-T., Zeng H., Qian M., Brogdon B.L., and Unger S.E. Anal. Chem. 72 (2000) 61
19. Ott G.R., Asakawa N., Liu R., Covington M.B., Qian M., Vaddi K., Newton R.C., Christ D.D., Trzaskos J.M., Gayla L., Scholz T., Marshall M., and Duan J.J.-W. Bioorg. Med. Chem. Lett. 18 (2008) 1288
20. For details of serum protein binding measurement, see. Cherney R.J., Duan J.J.-W., Voss M.E., Chen L., Wang L., Meyer D.T., Wasserman Z.R., Hardman K.D., Liu R.-Q., Covington M.B., Qian M., Mandlekar S., Christ D.D., Trzaskos J.M., Newton R.C., Magolda R.L., Wexler R.R., and Decicco C.P. J. Med. Chem. 46 (2003) 1811